MabVax Therapeutics Holdings Inc. (fka MBVXQ)

[sons4]

Finally, our unique platform opens us up to a myriad of partnership opportunities for the future, one of which is already in motion. Juno Therapeutics, which just got a $1 billion investment from pharma giant Celgene, is a pioneer in chimeric antigen receptor T cells, (CAR T cells) which are immune cells with specially tailored receptors on their cell membranes. These receptors are specifically designed to lock on to cancers, enabling the immune cell to recognize and attack the cancer. Our partnership with Juno gives them the option to use two sets of our antibodies as the targeting sequence for new CAR T cells targeting solid tumors.

Since we are the only company that harvests cancer antibodies directly from humans, it is very possible that Juno will not be the only multibillion dollar company we partner with, especially if our antibodies are successfully integrated into one of their products.

http://www.thechairmansblog.com/mabvax-therapeutics/david-hansen/introducing-mabvax-therapeutics/